RxDoctor Payments DataLook up a doctor →

Joseph Lee, MD

Procedural Dermatology · Bethesda, MDNPI 1518953074

Payments from drug & device makers

$12,635in general payments, 2019–2025

Across 676 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Galderma Laboratories, L.p.$923
  • Pfizer$781
  • Lilly USA, LLC$758
  • Arcutis Biotherapeutics, Inc.$686
  • plus $7K from 27 others

What the payments were for

  • Food & beverage$12,40998%
  • Education$2262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,003,820
Medicare patients
1,742
Services billed
18,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast17$132,740
VtamaTapinarof27$36,973
Doxycycline Ir-DrDoxycycline Monohydrate37$24,522
CiclopiroxCiclopirox Olamine419$11,508
Tacrolimus46$9,207
Metronidazole142$6,058
Betamethasone Dipropionate182$5,823
Pimecrolimus25$5,376
Ivermectin18$4,594
Clobetasol Propionate35$2,995
Triamcinolone Acetonide260$2,636
Doxycycline Hyclate105$2,178
Fluorouracil21$1,293
ValacyclovirValacyclovir Hcl46$1,233
Clindamycin Phosphate36$1,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$164$132,74017 claims
Dermavant Sciences, Inc.Vtama$479$36,97327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →